Drugs / Hologene 7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02984085 | Jan 2017 → Aug 2018 | recessive dystrophic epidermolysis bullosa | Holostem s.r.l. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hologene 7 | “Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent...” NCT02984085 ↗ |
| Action | Restore | “carrying COL7A1 complementary DNA (cDNA) for restoration of the epidermis” NCT02984085 ↗ |
| Modality | Cell therapy | “autologous cultured epidermal grafts containing epidermal stem cells genetically modified” NCT02984085 ↗ |
| Route | Other | “will be implanted into the selected area” NCT02984085 ↗ |